Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
about
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaAdvances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemiaLow dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.Allogeneic hematopoietic stem cell transplantation improves the prognosis of p16-deleted adult patients with acute lymphoblastic leukemia.
P2860
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
@en
type
label
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
@en
prefLabel
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
@en
P2093
P2860
P1433
P1476
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
@en
P2093
Daniel Lee
Michaela Liedtke
Shira Dinner
P2860
P304
P356
10.3109/10428194.2013.856428
P577
2014-04-25T00:00:00Z